A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)

Phase 1 Completed 32 enrolled Ampio Pharmaceuticals. Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase I study to evaluate the safety and efficacy of inhaled Ampion on patients with prolonged respiratory symptoms due to COVID-19 (Long COVID).

Timeline

Start: 2021-07-26
Primary completion: 2021-12-22
Completion: 2022-02-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ASPARTYL-ALANYL-DIKETOPIPERAZINE	Protein / enzyme biologic	—	Inhaled

A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)

Summary

Timeline

Drugs

Indications